Clustering of Missense Mutations in the C-Terminal Region of Factor H in Atypical Hemolytic Uremic Syndrome-Reference-Cited by-同舟云学术

Clustering of Missense Mutations in the C-Terminal Region of Factor H in Atypical Hemolytic Uremic Syndrome

Published:2001-02 Issue:2 Volume:68 Page:478-484
ISSN:0002-9297
Container-title:The American Journal of Human Genetics
language:en
Short-container-title:The American Journal of Human Genetics

Author:

Pérez-Caballero David,González-Rubio Carolina,Gallardo M.Esther,Vera Mariá,López-Trascasa Margarita,Rodríguez de Córdoba Santiago,Sánchez-Corral Pilar

Publisher

Elsevier BV

Subject

Genetics(clinical),Genetics

Reference36 articles.

1. Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H;Alsenz;Biochem J,1985

2. Factor H and the pathogenesis of renal diseases;Ault;Pediatr Nephrol,2000

3. Human factor H deficiency: mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism;Ault;J Biol Chem,1997

4. Identification of the second heparin-binding domain in human complement factor H;Blackmore;J Immunol,1998

5. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H;Blackmore;J Immunol,1996

Cited by 265 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement System and the Kidney: Its Role in Renal Diseases, Kidney Transplantation and Renal Cell Carcinoma;International Journal of Molecular Sciences;2023-11-20

2. Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?;International Journal of Molecular Sciences;2023-09-24

3. Various phenotypes of postpartum atypical hemolytic uremic syndrome: the role of genetic testing in determining prognosis. Case report;Terapevticheskii arkhiv;2023-08-17

4. Complement therapeutics are coming of age in rheumatology;Nature Reviews Rheumatology;2023-06-19

5. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome;Expert Review of Clinical Pharmacology;2023-05-04